Immunovant is a clinical-stage immunology company developing treatments for autoimmune diseases based on an anti-FcRN antibody strategy. The company's lead candidate, IMVT-1402, is a fully human monoclonal antibody administered as a subcutaneous injection designed to reduce pathogenic immunoglobulin G antibody levels, with clinical trials ongoing across multiple therapeutic areas including endocrine, neurological, rheumatology, and dermatology diseases. Immunovant has not yet generated revenue and finances its operations through research and development activities, including clinical trials and regulatory preparation, with the expectation that it will only generate revenue upon successful development and regulatory approval of IMVT-1402 or future candidates.